Loading market dashboard
Teva Pharmaceutical Industries Limited
TEVAHealthcareNYSEIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington's disease (HD) chorea3 and the effect of AUSTEDO® or AUSTEDO XR® on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.1 , 2 The data were presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, held June 4 – 8, 2026, in Washington, DC.
On June 02, 2026, Teva Pharmaceutical Industries Ltd (TEVA) shares fell 4.5% to a current price of $33.08. This decline comes in the context of a 52-week tradin
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M. Eastern Time.
Thanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound. Even after surging 90% higher over the past year, Teva's comeback may have additional runway.
Teva Pharmaceutical (TEVA) delivered a strong Q1 2026, reinforcing my buy rating and the company's successful pivot to innovative growth assets. TEVA's innovative neuroscience franchise—AUSTEDO, AJOVY, and Uzedy—drove $838M in Q1 revenue, up 41% year over year, offsetting legacy generics decline. Management maintained full-year guidance, with stable gross margins (52.9%) and a clear path to 30% non-GAAP operating income margin by 2027.
Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).
TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. TEV-‘749 aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.1
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency ("Fitch") has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB.
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+.
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California.
Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeline.
Teva's turnaround is real -- and may not be over.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time).
Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustainability targets, which are focused on the issues most relevant to its business, patients and the planet. Teva surpassed all 2025 targets associated with its sustainability-linked bonds—totaling approximately $7.5 billion across its 2021 and 2023 issuances. These commitments reflect progress in areas such as climate action, health equity and access to medicines, linking financial and sustainability performance.
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stocks are trading lower as tech and heavy anticipation surrounding today's Fed meeting and Powell speech
Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped by sales of its branded medicines.
For an accessible version of this Press Release, please visit www. tevapharm. com Q1 2026 revenues of ~$4. 0 billion increased by 2% in U. S.
For an accessible version of this Press Release, please visit www.tevapharm.com
PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in children with Tourette syndrome demonstrated statistically significant results on the study's primary efficacy endpoint, and the NDA submission is anticipated in 2H 2026.
Collectively, analysts tracking the stock expect declines in both revenue and profitability. The company continues to effect a major pivot in its business.
AE Wealth Management LLC trimmed its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 41.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,027 shares of the company's stock after selling 52,672 shares during the period.
FDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst. Teva's specialty drugs continue to gain momentum.
PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with community-informed and experienced-based information and support.
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities
Teva Pharmaceuticals is undergoing a strategic shift from generics to specialty branded medicines, complex generics, biosimilars, and innovation-led pipeline expansion. TEVA's key growth drivers include Austedo, Ajovy, Uzedy, and especially the late-stage immunology asset Duvakitug, which has shown compelling phase 2b efficacy and durability. Phase 2b data for Duvakitug in ulcerative colitis and Crohn's disease demonstrate robust remission rates and favorable safety, with multiple phase 3 trials underway.
Teva wins FDA approval for Prolia biosimilar Ponlimsi and secures Xolair biosimilar filing review by the FDA and EMA, strengthening its biosimilars push.
TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration (FDA) has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia ® , and Teva's applications for a proposed biosimilar candidate to Xolair ® (omalizumab) have been accepted by both the U.S. FDA and the European Medicines Agency (EMA).
E. Ohman J or Asset Management AB purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,680 shares of the company's stock, valued at approximately $614,000. A number of
Hudson Bay Capital Management LP grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 87.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,000 shares of the company's stock after acquiring an additional 105,000 shares during the
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website.
Stocks are soaring to start the new week, as falling oil prices and bond yields encourage investors
Capital International Investors boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,727,954 shares of the company's stock after purchasing an additional 18,966 shares during the period.
The Food and Drug Administration approved the drug leucovorin as a treatment for the rare genetic condition cerebral folate deficiency on Tuesday—but stopped short of approving it as a treatment for autism in general, an abrupt shift after members of the administration previously mentioned it as a potential therapy for the developmental disorder.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising precious metals prices.
